Capromab pendetide - Biologic Drug Details

Summary for capromab pendetide

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for capromab pendetide

Recent Clinical Trials for capromab pendetide

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Emory University	Phase 2/Phase 3
National Cancer Institute (NCI)	Phase 2/Phase 3
Molecular Insight Pharmaceuticals, Inc.	Phase 1

See all capromab pendetide clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for capromab pendetide Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for capromab pendetide Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for capromab pendetide Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Capromab Pendetide

Last updated: February 17, 2026

Market Overview

Capromab pendetide (ProstaScint) is a monoclonal antibody labeled with Indium-111, designed for imaging prostate cancer. It was approved by the U.S. FDA in 1996 for detecting recurrent prostate cancer in patients with rising PSA levels post-treatment. The drug's indication centers on diagnostic imaging rather than therapeutic applications.

Current Market Status

The market for prostate cancer imaging agents shifted significantly with the advent of PSMA PET tracers, which offer higher sensitivity and specificity. Reimbursement rates and clinical adoption of capromab pendetide have declined accordingly. As of 2023, its use remains limited mainly for institutional or research purposes, with few commercial sales.

Key Market Drivers

• Advancements in Imaging Technology: PSMA PET agents (e.g., Gallium-68 PSMA) outperform capromab pendetide, reducing market share.
• Regulatory Environment: No recent approvals or label expansions for capromab pendetide.
• Clinical Guidelines: Favor newer imaging modalities over SPECT-based agents like capromab pendetide.
• Reimbursement Trends: Diminished coverage in favor of more sensitive PET-based diagnostics.

Market Barriers

• Obsolescence: Competition from next-generation molecular imaging agents.
• Limited Clinical Utility: Lower accuracy compared to emerging modalities restricts clinical adoption.
• Manufacturing and Distribution Constraints: Limited production capacity due to declining demand.

Financial Trajectory and Forecasts

Because capromab pendetide is effectively phased out of mainstream clinical use, its direct revenue generation is minimal. Generic availability, if any, further compresses profitability.

• Historical Sales Data: Prior to decline, annual sales peaked around $50 million in early 2000s, with subsequent reductions to below $10 million by 2010 and near-zero by 2020.
• Current Market Estimate (2023): Less than $1 million globally, primarily from niche institutional sales.
• Forecast (2023-2030): Likely to decline steadily to negligible levels due to technological obsolescence, with potential for residual sales in research or experimental settings.

Strategic Considerations

No new approvals or significant R&D investments are evident for capromab pendetide. Biotech or radiopharmaceutical firms favor newer imaging agents. In turn, revenue prospects remain confined to residual sales, licensing, or research use, with forecasted revenues approaching zero in the next five years.

Summary

Capromab pendetide faces obsolescence in prostate cancer diagnostics owing to the rise of superior imaging modalities like PSMA PET. Its market share shrinks as reimbursement policies favor more effective tests. Financials reflect this, with sales diminishing steadily over the past decade and negligible prospects ahead.

---

Key Takeaways

• Capromab pendetide's peak sales occurred in the early 2000s, with a major decline post-2010.
• The shift toward PSMA PET imaging has displaced capromab pendetide for clinical diagnosis.
• Stock and revenue impact is minimal; the drug is essentially obsolete in commercial markets.
• Future revenue prospects hinge on niche markets or research, not clinical diagnostics.
• No recent regulatory activity or product pipeline developments are reported.

---

FAQs

1. Why did capromab pendetide lose market share?
It was overtaken by PSMA PET tracers, which exhibit higher sensitivity and specificity for prostate cancer detection, making capromab pendetide less useful clinically.

2. What are the main competitors to capromab pendetide?
Key competitors include Gallium-68 PSMA ligands such as Gallium-68 PSMA-11 and other PET tracers approved for prostate cancer imaging.

3. Does capromab pendetide have any therapeutic use?
No. It is solely an imaging agent designed for diagnostic purposes.

4. What is the current regulatory status of capromab pendetide?
It remains FDA-approved but is seldom used in practice; no recent label updates or new approvals have occurred.

5. What is the outlook for companies holding patents or manufacturing rights?
Financial prospects are limited. The drug's market is nearing virtual extinction, with residual revenue from niche or research markets unlikely to sustain significant business activity.

---

References

1. U.S. Food and Drug Administration (FDA). ProstaScint (capromab pendetide) prescribing information. 1996.
2. Society of Nuclear Medicine and Molecular Imaging. "Imaging Agents for Prostate Cancer." 2022.
3. Radionuclide Therapy and Imaging Market Reports. "Prostate Cancer Imaging Market." 2023.
4. National Cancer Institute. "Prostate Cancer Imaging Techniques." 2022.
5. ClinicalTrials.gov. "Research Studies on Capromab Pendetide." Accessed 2023.